<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">arthyper</journal-id><journal-title-group><journal-title xml:lang="ru">Артериальная гипертензия</journal-title><trans-title-group xml:lang="en"><trans-title>"Arterial’naya Gipertenziya" ("Arterial Hypertension")</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1607-419X</issn><issn pub-type="epub">2411-8524</issn><publisher><publisher-name>Antihypertensive League</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18705/1607-419X-2020-26-4-447-461</article-id><article-id custom-type="elpub" pub-id-type="custom">arthyper-1993</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Особенности ведения пациентов с неврологическими заболеваниями в период пандемии COVID-19</article-title><trans-title-group xml:lang="en"><trans-title>The management of patients with neurological diseases during the COVID-19 pandemic</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0175-3085</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Топузова</surname><given-names>М. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Topuzova</surname><given-names>M. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Топузова Мария Петровна — кандидат медицинских наук, доцент кафедры неврологии и психиатрии.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Mariya P. Topuzova, MD, PhD, Associate Professor, Department of Neurology and Psychiatry.</p><p>St Petersburg</p></bio><email xlink:type="simple">maria.topuzova@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4441-1165</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Алексеева</surname><given-names>Т. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Alekseeva</surname><given-names>T. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Алексеева Татьяна Михайловна — доктор медицинских наук, доцент, заведующая кафедрой неврологии и педиатрии.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Tat’yana M. Alekseeva, MD, PhD, DSc, Associate Professor, Head, Department of Neurology and Psychiatry.</p><p>St Petersburg</p></bio><email xlink:type="simple">alekseeva_tm@almazovcentre.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1140-8039</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чайковская</surname><given-names>А. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Chaykovskaya</surname><given-names>A. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Чайковская Александра Дмитриевна — клинический ор-динатор кафедры неврологии и психиатрии.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Alexandra D. Chaykovskaya, MD, Resident, Department of Neurology and Psychiatry.</p><p>St Petersburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0074-4021</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Терновых</surname><given-names>И. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Ternovyh</surname><given-names>I. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Терновых Иван Константинович — старший лаборант кафедры неврологии и психиатрии.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Ivan K. Ternovyh, MD, Senior Laboratory Assistant, Department of Neurology and Psychiatry.</p><p>St Petersburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3800-8270</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Исабекова</surname><given-names>П. Ш.</given-names></name><name name-style="western" xml:lang="en"><surname>Isabekova</surname><given-names>P. Sh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Исабекова Патимат Шамильевна — клинический ординатор кафедры неврологии и психиатрии.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Patimat Sh. Isabekova, MD, Resident, Department of Neurology and Psychiatry.</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное учреждение Национальный медицинский исследовательский центр имени B.A. Алмaзoвa Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Almazov National Medical Research Centre</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>28</day><month>08</month><year>2020</year></pub-date><volume>26</volume><issue>4</issue><fpage>447</fpage><lpage>461</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Топузова М.П., Алексеева Т.М., Чайковская А.Д., Терновых И.К., Исабекова П.Ш., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Топузова М.П., Алексеева Т.М., Чайковская А.Д., Терновых И.К., Исабекова П.Ш.</copyright-holder><copyright-holder xml:lang="en">Topuzova M.P., Alekseeva T.M., Chaykovskaya A.D., Ternovyh I.K., Isabekova P.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://htn.almazovcentre.ru/jour/article/view/1993">https://htn.almazovcentre.ru/jour/article/view/1993</self-uri><abstract><p>В статье рассмотрены особенности ведения пациентов с различными неврологическими заболеваниями в период пандемии COVID-19, с учетом определения уровня риска заражения. Указана возможность увеличения риска заражения у пациентов при наличии инвалидизации, особенно с нарушением функции дыхательной и бульбарной мускулатуры, ограничением подвижности, наличием сопутствующих забо-леваний. Описаны рекомендации по лечению пациентов с инсультом, нервно-мышечными заболеваниями, воспалительными и аутоиммунными заболеваниями центральной нервной системы, в частности, рассеянного склероза и заболеваний спектра нейрооптикомиелита, а также невоспалительными заболеваниями центральной нервной системы (эпилепсия, болезнь Паркинсона, атипичный паркинсонизм, дистония, наследственная спастическая параплегия, детский церебральный паралич, доброкачественная внутричерепная гипертензия). Приведены взаимодействия препаратов для лечения COVID-19 и неврологических заболеваний. Отмечены потенциальные неврологические осложнения COVID-19: аносмия, агевзия, вирусный менингит, энцефалит, постинфекционный стволовой энцефалит, острая некротизирующая геморрагическая лейкоэнцефалопатия, синдром Гийена-Барре, миозиты. Подчеркнута важность того, что во время пандемии COVID-19, при обследовании пациентов с неврологическими заболеваниями клиницисты должны учитывать возможность наличия у пациента с COVID-19, а также рассматривать его как дифференциальный диагноз, чтобы избежать ошибок диагностики, назначить своевременное лечение и предотвратить распространение инфекции.</p></abstract><trans-abstract xml:lang="en"><p>The article discusses the management of patients with various neurological diseases during the COVID-19 pandemic, taking into account the determination of the level of risk of infection. The possibility of increasing the risk of infection in patients with disability, especially with impaired function of the respiratory and bulbar muscles, limited mobility, and the presence of concomitant diseases, is indicated. The recommendations on the treatment of patients with stroke, neuromuscular diseases, inflammatory and autoimmune diseases of the central nervous system, in particular, multiple sclerosis and neuromyelitis optica spectrum disorder (NMOSD), as well as non-inflammatory diseases of the central nervous system (epilepsy, Parkinson’s disease, atypical parkinsonism, dystonia, hereditary spastic paraplegia, infantile cerebral palsy, benign intracranial hypertension) are considered. Interactions of drugs for the treatment of COVID-19 and neurological diseases are given. Potential neurological complications of COVID-19 are overviewed. Potential neurological complications of COVID-19 were noted: anosmia, ageusia, viral meningitis, encephalitis, post-infectious stem encephalitis, acute necrotizing hemorrhagic leukoencephalopathy, Guillain-Barre syndrome, myositis. The importance of the fact that during the COVID-19 pandemic, when examining patients with neurological diseases, clinicians should take into account the possibility of a patient with COVID-19, and also consider it as a differential diagnosis in order to avoid diagnostic errors, prescribe timely treatment and prevent the spread of infection.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>коронавирус</kwd><kwd>инсульт</kwd><kwd>нервно-мышечные заболевания</kwd><kwd>рассеянный склероз</kwd><kwd>заболевания спектра нейрооптикомиелита</kwd><kwd>эпилепсия</kwd><kwd>болезнь Паркинсона</kwd><kwd>невро-логические осложнения COVID-19</kwd></kwd-group><kwd-group xml:lang="en"><kwd>SARS-CoV-2</kwd><kwd>coronavirus</kwd><kwd>stroke</kwd><kwd>neuromuscular disease</kwd><kwd>multiple sclerosis</kwd><kwd>neuromyelitis optica spectrum disorder (NMOSD)</kwd><kwd>epilepsy</kwd><kwd>Parkinson’s disease</kwd><kwd>neurological complications of COVID-19</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Временные методические рекомендации Минздрава России «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). М., 2020. Версия 7 (03.06.2020)». [Электронный ресурс]. URL: https://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/584/original/03062020_%D0%9CR_COVID-19_v7.pdf.</mixed-citation><mixed-citation xml:lang="en">Temporary methodological recommendations of Ministry of health of Russia “Prevention, diagnosis and treatment of the new coronavirus infection (COVID-19). M., 2020. Version 7(03.06.2020)”. Available from: https://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/584/original/03062020_%D0%9CR_COVID-19_v7.pdf. In Russian.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Методические рекомендации, алгоритмы действия медицинских работников на различных этапах оказания помощи, чек-листы и типовые документы, разработанные на период наличия и угрозы дальнейшего распространения новой коронавирусной инфекции в Санкт-Петербурге. Версия 2,0 (01.06.2020). Санкт-Петербург, 2020. [Электронный ресурс]. URL: http://zdrav.spb.ru/media/komzdrav/documents/document/file/Brochure_COVID-19_24.04_%D1%81%D0%BE%D0%BA%D1%80.pdf.</mixed-citation><mixed-citation xml:lang="en">Guidelines, algorithms for medical workers at various stages of care, checklists and standard documents developed for the period of presence and threat of further spread of a new coronavirus infection in St. Petersburg. Version 2.0 (01.06.2020). St Petersburg, 2020. Available from: http://zdrav.spb.ru/media/komzdrav/documents/document/file/Brochure_COVID-19_24.04_%D1%81%D0%BE%D0%BA%D1%80.pdf. In Russian.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">ABN Executive in association with subspecialist Advisory groups. Association of British Neurologists Guidance on COVID-19 for people with neurological conditions, their doctors and carers. Version 6 (09.04.2020). Available from: https://cdn.ymaws.com/www.theabn.org/resource/collection/65C334C7-30FA-45DB-93AA-74B3A3A20293/ABN_Neurology_COVID-19_Guidance_v6_9.4.20_FP.pdf</mixed-citation><mixed-citation xml:lang="en">ABN Executive in association with subspecialist Advisory groups. Association of British Neurologists Guidance on COVID-19 for people with neurological conditions, their doctors and carers. Version 6 (09.04.2020). Available from: https://cdn.ymaws.com/www.theabn.org/resource/collection/65C334C7-30FA-45DB-93AA-74B3A3A20293/ABN_Neurology_COVID-19_Guidance_v6_9.4.20_FP.pdf</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Interaction checker. COVID-19 drug interaction. University of Liverpool. Available from: https://www.covid19druginteractions.org</mixed-citation><mixed-citation xml:lang="en">Interaction checker. COVID-19 drug interaction. University of Liverpool. Available from: https://www.covid19druginteractions.org</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Zh et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: aretrospective cohort study. Lancet. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3</mixed-citation><mixed-citation xml:lang="en">Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Zh et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: aretrospective cohort study. Lancet. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Mao L, Jin H, Wang M, Hu Y, Chen S, He Q et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020:77(6)1-9. doi:10.1001/jamaneurol.2020.1127</mixed-citation><mixed-citation xml:lang="en">Mao L, Jin H, Wang M, Hu Y, Chen S, He Q et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020:77(6)1-9. doi:10.1001/jamaneurol.2020.1127</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Benussi A, Pilotto A, Premi E, Libri I, Giunta M, Agosti C et al. Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in Brescia, Lombardy, Italy. Neurology. 2020. [Ahead of print, published online May 22, 2020]. doi:10.1212/WNL.0000000000009848.</mixed-citation><mixed-citation xml:lang="en">Benussi A, Pilotto A, Premi E, Libri I, Giunta M, Agosti C et al. Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in Brescia, Lombardy, Italy. Neurology. 2020. [Ahead of print, published online May 22, 2020]. doi:10.1212/WNL.0000000000009848.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Morassi M, Bagatto D, Cobelli M, D’Agostini S, Gigli GL, Bna C et al. Stroke in patients with SARS-CoV-2 infection: case series. J Neurol. 2020. [Ahead of print, published online May 20, 2020]. doi:10.1007/s00415-020-09885-2</mixed-citation><mixed-citation xml:lang="en">Morassi M, Bagatto D, Cobelli M, D’Agostini S, Gigli GL, Bna C et al. Stroke in patients with SARS-CoV-2 infection: case series. J Neurol. 2020. [Ahead of print, published online May 20, 2020]. doi:10.1007/s00415-020-09885-2</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Guo T, Fan Y, Chen M, Wu X, Zhang L, He T et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020; e201017. doi:10.1001/jamacardio.2020.1017</mixed-citation><mixed-citation xml:lang="en">Guo T, Fan Y, Chen M, Wu X, Zhang L, He T et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020; e201017. doi:10.1001/jamacardio.2020.1017</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094-1099. doi:10.1111/jth.14817</mixed-citation><mixed-citation xml:lang="en">Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094-1099. doi:10.1111/jth.14817</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Iba T, Levy JH, Warkentin TE, Thachil J, van der Poll T, Levi M. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost. 2019;17(11):1989-1994. doi:10.1111/jth.14578</mixed-citation><mixed-citation xml:lang="en">Iba T, Levy JH, Warkentin TE, Thachil J, van der Poll T, Levi M. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost. 2019;17(11):1989-1994. doi:10.1111/jth.14578</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Wang J, Hajizadeh N, Moore EE, McIntyre RC, Moore PK, Veress LA et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a caseseries. J Thromb Haemost. 2020;18(7):1752-1755. doi:10.1111/jth.14828</mixed-citation><mixed-citation xml:lang="en">Wang J, Hajizadeh N, Moore EE, McIntyre RC, Moore PK, Veress LA et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a caseseries. J Thromb Haemost. 2020;18(7):1752-1755. doi:10.1111/jth.14828</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, hostvirus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci. 2020:11(7):995-998. doi:10.1021/acschemneuro.0c00122</mixed-citation><mixed-citation xml:lang="en">Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, hostvirus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci. 2020:11(7):995-998. doi:10.1021/acschemneuro.0c00122</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Doobay MF, Talman LS, Obr TD, Tian X, Davisson RL, Lazartigues E. Differential expression of neuronal ACE 2 in transgenic mice with overexpression of the brain renin-angiotensin sys-tem. Am J Physiol Regul Integr Comp Physiol. 2007;292(1): R 373-R 381. doi:10.1152/ajpregu.00292.2006</mixed-citation><mixed-citation xml:lang="en">Doobay MF, Talman LS, Obr TD, Tian X, Davisson RL, Lazartigues E. Differential expression of neuronal ACE 2 in transgenic mice with overexpression of the brain renin-angiotensin sys-tem. Am J Physiol Regul Integr Comp Physiol. 2007;292(1): R 373-R 381. doi:10.1152/ajpregu.00292.2006</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450-454. doi:10. 1038/nature02145</mixed-citation><mixed-citation xml:lang="en">Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450-454. doi:10.1038/nature02145</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W et al. A pneumonia outbreak associated with a new coronavirus of probable at origin. Nature. 2020;579(7798):270-273. doi: 10.1038/s41586-020-2012-7</mixed-citation><mixed-citation xml:lang="en">Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W et al. A pneumonia outbreak associated with a new coronavirus of probable at origin. Nature. 2020;579(7798):270-273. doi: 10.1038/s41586-020-2012-7</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S et al. SARS-CoV-2 cell entry depends on ACE 2 and TMPRSS 2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280.e8. doi:10.1016/j.cell.2020.02.052</mixed-citation><mixed-citation xml:lang="en">Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S et al. SARS-CoV-2 cell entry depends on ACE 2 and TMPRSS 2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280.e8. doi:10.1016/j.cell.2020.02.052</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Chen J, Xiao X, Chen S, Zhang C, Chen J, Yi D et al. Angiotensin-converting enzyme 2 priming enhances the function of endothelialprogenitor cells and their therapeutic efficacy. Hypertension. 2013;61(3):681-689. doi:10.1161/HYPERTENSIONAHA.111.00202</mixed-citation><mixed-citation xml:lang="en">Chen J, Xiao X, Chen S, Zhang C, Chen J, Yi D et al. Angiotensin-converting enzyme 2 priming enhances the function of endothelialprogenitor cells and their therapeutic efficacy. Hypertension. 2013;61(3):681-689. doi:10.1161/HYPERTENSIONAHA.111.00202</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Chen J, Zhao Y, Chen S, Wang J, Xiao X, Ma X et al. Neuronalover-expression of ACE 2 protects brain from ischemiainduced damage. Neuropharmacology. 2014;79:550-558. doi:10.1016/j.neuropharm.2014.01.004</mixed-citation><mixed-citation xml:lang="en">Chen J, Zhao Y, Chen S, Wang J, Xiao X, Ma X et al. Neuronalover-expression of ACE 2 protects brain from ischemiainduced damage. Neuropharmacology. 2014;79:550-558. doi:10.1016/j.neuropharm.2014.01.004</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may be at least partially responsible for the respiratory failure of COVID-19 patients. J Med Virol. 2020:92(6):552-555. doi:10.1002/jmv.25728</mixed-citation><mixed-citation xml:lang="en">Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may be at least partially responsible for the respiratory failure of COVID-19 patients. J Med Virol. 2020:92(6):552-555. doi:10.1002/jmv.25728</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Мартынов М. Ю., Шамалов Н. А., Хасанова Д. Р, Вознюк И.А., Алашеев А. М., Харитонова Т. В. и др. Ведение пациентов с острыми нарушениями мозгового кровообращения в контексте пандемии COVID-19. Временные методические рекомендации. Версия 2 (16.04.2020). [Электронный ресурс]. URL: http://education.almazovcentre.ru/wp-content/uploads/2020/04/VR-Vedenie-patcientov-s-onmk-v-kontekste-pandemii-COVID-19.pdf.</mixed-citation><mixed-citation xml:lang="en">Martynov MYu, Shamalov NA, Hasanova DR, Wozniuk IA, Alasheev AM, Kharitonova TV et al. Management of patients with acute stroke in the context of COVID-19 pandemic. Temporary methodological recommenda-tions. Version 2 (16.04.2020). Available from: http://education.almazovcentre.ru/wp-content/uploads/2020/04/VR-Vedenie-patcientov-s-onmk-v-kontekstepandemii-COVID-19.pdf. In Russian.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Baracchini C, Pieroni A, Viaro F, Cianci V, Cattelan AM, Tiberio I et al. Acute stroke management pathway during Coronavirus-19 pandemic. Neurol Sci. 2020;41(5): 1003-1005. doi: 10.1007/s10072-020-04375-9</mixed-citation><mixed-citation xml:lang="en">Baracchini C, Pieroni A, Viaro F, Cianci V, Cattelan AM, Tiberio I et al. Acute stroke management pathway during Coronavirus-19 pandemic. Neurol Sci. 2020;41(5): 1003-1005. doi: 10.1007/s10072-020-04375-9</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Jin H, Hong C, Chen S, Zhou Y, Wang Y, Mao L et al. Consensus for prevention and management of coronavirus disease 2019 (COVID-19) for neurologists. Stroke Vasc Neurol. 2020;5(2):146-151. doi:10.1136/svn-2020-000382</mixed-citation><mixed-citation xml:lang="en">Jin H, Hong C, Chen S, Zhou Y, Wang Y, Mao L et al. Consensus for prevention and management of coronavirus disease 2019 (COVID-19) for neurologists. Stroke Vasc Neurol. 2020;5(2):146-151. doi:10.1136/svn-2020-000382</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Monteil V, Kwon H, Prado P, Hagelkruys A, Wimmer RA. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE 2. 2020;181(4):905-913. e7. doi:10. 1016/j.cell.2020.04.004</mixed-citation><mixed-citation xml:lang="en">Monteil V, Kwon H, Prado P, Hagelkruys A, Wimmer RA. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE 2. 2020;181(4):905-913. e7. doi:10.1016/j.cell.2020.04.004</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Hess DC, Eldahshan W, Rutkowski E. COVID-19-Related Stroke. Transl Stroke Res. 2020;11(3):322-325. doi:10.1007/s12975-020-00818-9</mixed-citation><mixed-citation xml:lang="en">Hess DC, Eldahshan W, Rutkowski E. COVID-19-Related Stroke. Transl Stroke Res. 2020;11(3):322-325. doi:10.1007/s12975-020-00818-9</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Detailed recommendations for interactions with experi-mental COVID-19 antiviral therapies. Updated 04 June 2020. Available from: https://www.covid19-druginteractions.org</mixed-citation><mixed-citation xml:lang="en">Detailed recommendations for interactions with experi-mental COVID-19 antiviral therapies. Updated 04 June 2020. Available from: https://www.covid19-druginteractions.org</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E et al. Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(23):2950-2973. doi:10.1016/j.jacc.2020.04.031</mixed-citation><mixed-citation xml:lang="en">Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E et al. Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(23):2950-2973. doi:10.1016/j.jacc.2020.04.031</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Gummi RR, Kukulka NA, Deroche CB, Govindarajan R. Factors associated with acuteexacerbations of myasthenia gravis. Muscle Nerve. 2019;60(6):693-699. doi:10.1002/mus.26689</mixed-citation><mixed-citation xml:lang="en">Gummi RR, Kukulka NA, Deroche CB, Govindarajan R. Factors associated with acuteexacerbations of myasthenia gravis. Muscle Nerve. 2019;60(6):693-699. doi:10.1002/mus.26689</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Guidelines for the neuromuscular service, national hospital for neurology and neurosurgery general health advice (from DHSC/ PHE/FCO, updated 23 March 2020). Available from: https://www.ucl.ac.uk/centre-for-neuromuscular-diseases/sites/centre-forneuromuscular-diseases/files/coronavirus_nd_message_6_4.pdf</mixed-citation><mixed-citation xml:lang="en">Guidelines for the neuromuscular service, national hospital for neurology and neurosurgery general health advice (from DHSC/ PHE/FCO, updated 23 March 2020). Available from: https://www.ucl.ac.uk/centre-for-neuromuscular-diseases/sites/centre-forneuromuscular-diseases/files/coronavirus_nd_message_6_4.pdf</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Guidon AC, Amato AA. COVID-19 and neuromuscular disorders. Neurology. 2020;94(22):959-969. doi:10.1212/WNL.0000000000009566</mixed-citation><mixed-citation xml:lang="en">Guidon AC, Amato AA. COVID-19 and neuromuscular disorders. Neurology. 2020;94(22):959-969. doi:10.1212/WNL.0000000000009566</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">International MG/COVID-19 Working Group. Jacob S, Muppidi S, Guidon A, Guptill J, Hehir M, Howard JF et al. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. J Neurol Sci. 2020;412:116803. doi:10.1016/j.jns.2020.116803</mixed-citation><mixed-citation xml:lang="en">International MG/COVID-19 Working Group. Jacob S, Muppidi S, Guidon A, Guptill J, Hehir M, Howard JF et al. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. J Neurol Sci. 2020;412:116803. doi:10.1016/j.jns.2020.116803</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Sole G, Salort-Campana E, Pereon Y, Stojkovic T, Wahbi K, Cintas P et al. FILNEMUS COVID-19 study group. Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network. Rev Neurol (Paris). 2020;176(6):507-515. doi:10. 1016/j.neurol.2020.04.004</mixed-citation><mixed-citation xml:lang="en">Sole G, Salort-Campana E, Pereon Y, Stojkovic T, Wahbi K, Cintas P et al. FILNEMUS COVID-19 study group. Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network. Rev Neurol (Paris). 2020;176(6):507-515. doi:10.1016/j.neurol.2020.04.004</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi:10.1016/S01406736(20)30183-5</mixed-citation><mixed-citation xml:lang="en">Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi:10.1016/S01406736(20)30183-5</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barre syndrome associated withSARS-CoV-2 infection: causality or coincidence? Lancet Neurol. 2020;19(5):383-384. doi:10.1016/S1474-4422(20)30109-5</mixed-citation><mixed-citation xml:lang="en">Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barre syndrome associated withSARS-CoV-2 infection: causality or coincidence? Lancet Neurol. 2020;19(5):383-384. doi:10.1016/S1474-4422(20)30109-5</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Camdessanche JP, Morel J, Pozzetto B, Paul S, Tholance Y, Botelho-Nevers E. COVID-19 may induce Guillain-Barre syndrome. Rev Neurol (Paris). 2020;176(6):516-518. doi:10.1016/j.neurol.2020.04.003</mixed-citation><mixed-citation xml:lang="en">Camdessanche JP, Morel J, Pozzetto B, Paul S, Tholance Y, Botelho-Nevers E. COVID-19 may induce Guillain-Barre syndrome. Rev Neurol (Paris). 2020;176(6):516-518. doi:10.1016/j.neurol.2020.04.003</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Sedaghat Z, Karimi N. Guillain-Barre syndrome associated with COVID-19 infection: a case report. J Clin Neurosci. 2020;76:233-235. doi:10.1016/jjocn.2020.04.062.</mixed-citation><mixed-citation xml:lang="en">Sedaghat Z, Karimi N. Guillain-Barre syndrome associated with COVID-19 infection: a case report. J Clin Neurosci. 2020;76:233-235. doi:10.1016/jjocn.2020.04.062.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG et al. Guillain-Barre syndrome associated with SARSCoV-2. N Engl J Med. 2020;382(26):2574-2576. doi:10.1056/NEJMc2009191.</mixed-citation><mixed-citation xml:lang="en">Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG et al. Guillain-Barre syndrome associated with SARSCoV-2. N Engl J Med. 2020;382(26):2574-2576. doi:10.1056/NEJMc2009191.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Otmani H, Moutawakil B, Rafai MA, Benna N, Kettani C, Soussi M et al. Covid-19 and Guillain-Barre Syndrome: More Than a Coincidence! Rev Neurol (Paris). 2020;176(6):518-519. doi:10. 1016/j.neurol.2020.04.007</mixed-citation><mixed-citation xml:lang="en">Otmani H, Moutawakil B, Rafai MA, Benna N, Kettani C, Soussi M et al. Covid-19 and Guillain-Barre Syndrome: More Than a Coincidence! Rev Neurol (Paris). 2020;176(6):518-519. doi:10. 1016/j.neurol.2020.04.007</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Benveniste O, Longuet P, Duval X, Le Moing V, Leport C, Vilde JL. Two episodes of acute renal failure, rhabdomyolysis, and severe hepatitis in an AIDS patient successively treated with ritonavir and indinavir. Clin Infect Dis. 1999;28(5):1180-1181. doi:10.1086/517777</mixed-citation><mixed-citation xml:lang="en">Benveniste O, Longuet P, Duval X, Le Moing V, Leport C, Vilde JL. Two episodes of acute renal failure, rhabdomyolysis, and severe hepatitis in an AIDS patient successively treated with ritonavir and indinavir. Clin Infect Dis. 1999;28(5):1180-1181. doi:10.1086/517777</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Mah Ming JB, Gill MJ. Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV. AIDS Patient Care STDS. 2003;17(5):207-210. doi:10.1089/108729103321655854</mixed-citation><mixed-citation xml:lang="en">Mah Ming JB, Gill MJ. Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV. AIDS Patient Care STDS. 2003;17(5):207-210. doi:10.1089/108729103321655854</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Eadie MJ, Ferrier TM. Chloroquine myopathy. J Neurol Neurosurg Psychiatry. 1966;29(4):331-337. doi:10.1136/jnnp.29.4.331</mixed-citation><mixed-citation xml:lang="en">Eadie MJ, Ferrier TM. Chloroquine myopathy. J Neurol Neurosurg Psychiatry. 1966;29(4):331-337. doi:10.1136/jnnp.29.4.331</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Joyce E, Fabre A, Mahon N. Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literaturereview. Eur Heart J Acute Cardiovasc Care. 2013;2(1):77-83.</mixed-citation><mixed-citation xml:lang="en">Joyce E, Fabre A, Mahon N. Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literaturereview. Eur Heart J Acute Cardiovasc Care. 2013;2(1):77-83.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Estes ML, Ewing-Wilson D, Chou SM, Mitsumoto H, Hanson M, Shirey E et al. Chloroquine neuromyotoxicity: clinical and pathological perspective. Am J Med. 1987;82(3):447-455.</mixed-citation><mixed-citation xml:lang="en">Estes ML, Ewing-Wilson D, Chou SM, Mitsumoto H, Hanson M, Shirey E et al. Chloroquine neuromyotoxicity: clinical and pathological perspective. Am J Med. 1987;82(3):447-455.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Doughty CT, Amato AA. Toxic myopathies. Continuum (Minneap Minn). 2019;25(6):1712-1731. doi: 10.1212/CON.0000000000000806</mixed-citation><mixed-citation xml:lang="en">Doughty CT, Amato AA. Toxic myopathies. Continuum (Minneap Minn). 2019;25(6):1712-1731. doi: 10.1212/CON.0000000000000806</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Jallouli M, Saadoun D, Eymard B, Leroux G, Haroche J, Le Thi Huong D et al. The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature. J Neurol. 2012;259(7):1290-1297. doi:10.1007/s00415-011-6335-z</mixed-citation><mixed-citation xml:lang="en">Jallouli M, Saadoun D, Eymard B, Leroux G, Haroche J, Le Thi Huong D et al. The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature. J Neurol. 2012;259(7):1290-1297. doi:10.1007/s00415-011-6335-z</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Gummi RR, Kukulka NA, Deroche CB, Govindarajan R. Factors associated with acute exacerbations of myasthenia gravis. Muscle Nerve. 2019;60(6):693-699. doi:10.1002/mus.26689</mixed-citation><mixed-citation xml:lang="en">Gummi RR, Kukulka NA, Deroche CB, Govindarajan R. Factors associated with acute exacerbations of myasthenia gravis. Muscle Nerve. 2019;60(6):693-699. doi:10.1002/mus.26689</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Медицинская ассоциация врачей и центров рассеянного склероза и других нейроиммунологических заболеваний (МАВРС). Рекомендации по тактике ведения пациентов с рас-сеянным склерозом, в период пандемии коронавирусной инфекции COVID-19 (22.03.2020). [Электронный ресурс]. URL: https://www.centrems.com/downloads/MAVRS-COVID-19.pdf.</mixed-citation><mixed-citation xml:lang="en">Medical association of doctors and centers of MS and other neuro-immunology diseases (MAVRS). Guideline for treating patients with Multiple Sclerosis during the COVID-19 pandemic (22.03.2020). Available from: https://www.centrems.com/down-loads/MAVRSCOVID-19.pdf In Russian.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Бойко А. Н., Лащ Н. Ю., Спирин Н. Н., Сиверцева С. А., Мартынов М. Ю. Ведение пациентов с рассеянным склерозом в условиях пандемии COVID-19. Временные методические рекомендации. Версия 1. (19.04.2020). [Электронный ресурс]. URL: https://www.ructrims.org/files/2020/%D0%A0%D0%A1_%D0%B8_COVID19_%D0%A0%D0%B5%D0%BA%D0%BE%D0%BC%D0%B5%D0%BD%D0%B4%D0%B0%D1%86%D0%B8%D0%B8_%D0%92%D0%9E%D0%9D.pdf.</mixed-citation><mixed-citation xml:lang="en">Bojko A.N., Lashch N. Yu., Spirin N. N., Sivertseva S.A., Martynov M. Yu. Management of patients with Multiple Sclerosis in the context of COVID-19 pandemic. Temporary methodological recommendations. Version 1. (19.04.2020). Available from: https://www.ructrims.org/files/2020/%D0%A0%D0%A1_%D0%B8_COVID19_%D0%A0%D0%B5%D0%BA%D0%BE%D0%BC%D0%B5%D0%BD%D0%B4%D0%B0%D1%86%D0%B8%D0%B8_%D0%92%D0%9E%D0%9D.pdf. In Russian.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Giovannoni G, Hawkes C, Lechner-Scott J, Levy M, Waubant E, Gold J. The COVID-19 pandemic and the use of MS disease-modifying therapies. Mult Scler Relat Disord. 2020;39:102073. doi:10.1016/j.msard.2020.102073</mixed-citation><mixed-citation xml:lang="en">Giovannoni G, Hawkes C, Lechner-Scott J, Levy M, Waubant E, Gold J. The COVID-19 pandemic and the use of MS disease-modifying therapies. Mult Scler Relat Disord. 2020;39:102073. doi:10.1016/j.msard.2020.102073</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Brownlee W, Bourdette D, Broadley S, Killestein J, Ciccarelli O. Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic. Neurology. 2020;94(22):949-952. doi:10.1212/WNL.0000000000009507</mixed-citation><mixed-citation xml:lang="en">Brownlee W, Bourdette D, Broadley S, Killestein J, Ciccarelli O. Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic. Neurology. 2020;94(22):949-952. doi:10.1212/WNL.0000000000009507</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Baker D, Amor S, Kang AS, Schmierer K, Giovannoni G. The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic. Mult Scler Relat Disord. 2020;43:102174. doi:10.1016/j.msard.2020.102174</mixed-citation><mixed-citation xml:lang="en">Baker D, Amor S, Kang AS, Schmierer K, Giovannoni G. The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic. Mult Scler Relat Disord. 2020;43:102174. doi:10.1016/j.msard.2020.102174</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Guidance for health professionals managing neuromyelitis optica spectrum disorder (nmosd) in response to the threat of widespread covid-19 infection. Available from: http://www.nmouk.nhs.uk/healthcare-professionals/covid-19-guidance-forprofessionals</mixed-citation><mixed-citation xml:lang="en">Guidance for health professionals managing neuromyelitis optica spectrum disorder (nmosd) in response to the threat of widespread covid-19 infection. Available from: http://www.nmouk.nhs.uk/healthcare-professionals/covid-19-guidance-forprofessionals</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">NMOSD UK Service. Latest Covid-19 information for our patients. Posted on: June 1st, 2020 by nmouknhs. Available from: http://www.nmouk.nhs.uk/latest-covid-19-information-forour-patients</mixed-citation><mixed-citation xml:lang="en">NMOSD UK Service. Latest Covid-19 information for our patients. Posted on: June 1st, 2020 by nmouknhs. Available from: http://www.nmouk.nhs.uk/latest-covid-19-information-forour-patients</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, Host-Virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci. 2020;11(7):995-998. doi:10.1021/acschemneuro.0c00122</mixed-citation><mixed-citation xml:lang="en">Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, Host-Virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci. 2020;11(7):995-998. doi:10.1021/acschemneuro.0c00122</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Li YC, Bai WZ, Hashikawa T. Tsutomu Hashikawa the neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. 2020;92(6):552-555. doi:10.1002/jmv.25728</mixed-citation><mixed-citation xml:lang="en">Li YC, Bai WZ, Hashikawa T. Tsutomu Hashikawa the neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. 2020;92(6):552-555. doi:10.1002/jmv.25728</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Nath A. Neurologic complications of coronavirus infections. Neurology. 2020;94(19):809-810. doi:10.1212/WNL.0000000000009455</mixed-citation><mixed-citation xml:lang="en">Nath A. Neurologic complications of coronavirus infections. Neurology. 2020;94(19):809-810. doi:10.1212/WNL.0000000000009455</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Hepburn M, Mullaguri N, George P, Hantus S, Punia V, Bhimraj A et al. Acute Symptomatic Seizures in Critically Ill Patients with COVID-19: Is There an Association? Neurocrit Care. 2020. [Ahead of print, published online May 28, 2020]. doi:10.1007/s12028-020-01006-1</mixed-citation><mixed-citation xml:lang="en">Hepburn M, Mullaguri N, George P, Hantus S, Punia V, Bhimraj A et al. Acute Symptomatic Seizures in Critically Ill Patients with COVID-19: Is There an Association? Neurocrit Care. 2020. [Ahead of print, published online May 28, 2020]. doi:10. 1007/s12028-020-01006-1</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">French JA, Brodie MJ, Caraballo R, Devinsky O, Ding D, Jehi L et al. Keeping people with epilepsy safe during the COVID-19 pandemic. Neurology. 2020;94(23):1032-1037. doi: 10.1212/WNL.0000000000009632</mixed-citation><mixed-citation xml:lang="en">French JA, Brodie MJ, Caraballo R, Devinsky O, Ding D, Jehi L et al. Keeping people with epilepsy safe during the COVID-19 pandemic. Neurology. 2020;94(23):1032-1037. doi: 10.1212/WNL.0000000000009632</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Sodhi M, Etminan M. Safety of ibuprofen in patients with COVID-19: causal or confounded? Chest. 2020;158(1):55-56. doi:10. 1016/j.chest.2020.03.040</mixed-citation><mixed-citation xml:lang="en">Sodhi M, Etminan M. Safety of ibuprofen in patients with COVID-19: causal or confounded? Chest. 2020;158(1):55-56. doi:10.1016/j.chest.2020.03.040</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Rey NL, Wesson DW, Brundin P. The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases. Neurobiol Dis. 2018;109(Pt B):226-248. doi:10.1016/j.nbd.2016.12.013</mixed-citation><mixed-citation xml:lang="en">Rey NL, Wesson DW, Brundin P. The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases. Neurobiol Dis. 2018;109(Pt B):226-248. doi:10.1016/j.nbd.2016.12.013</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Tulisiak CT, Mercado G, Peelaerts W, Brundin L, Brundin P. Can infections trigger alpha-synucleinopathies? Prog Mol Biol Transl Sci. 2019;168:299-322. doi:10.1016/bs.pmbts.2019.06.002</mixed-citation><mixed-citation xml:lang="en">Tulisiak CT, Mercado G, Peelaerts W, Brundin L, Brundin P. Can infections trigger alpha-synucleinopathies? Prog Mol Biol Transl Sci. 2019;168:299-322. doi:10.1016/bs.pmbts.2019.06.002</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Jo T, Yasunaga H, Michihata N, Sasabuchi Y, Hasegawa W, Takeshima H et al. Influence of Parkinsonism on outcomes of elderly pneumonia patients. Parkinsonism Relat Disord. 2018;54:25-29. doi:10.1016/j.parkreldis.2018.03.028</mixed-citation><mixed-citation xml:lang="en">Jo T, Yasunaga H, Michihata N, Sasabuchi Y, Hasegawa W, Takeshima H et al. Influence of Parkinsonism on outcomes of elderly pneumonia patients. Parkinsonism Relat Disord. 2018;54:25-29. doi:10.1016/j.parkreldis.2018.03.028</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Lubomski M, Rushworth RL, Tisch S. Hospitalisation and comorbidities in Parkinson’s Disease: a Large Australian Retrospective Study. J Neurol Neurosurg Psychiatry. 2015;86(3):32430. doi:10.1136/jnnp-2014-307822</mixed-citation><mixed-citation xml:lang="en">Lubomski M, Rushworth RL, Tisch S. Hospitalisation and comorbidities in Parkinson’s Disease: a Large Australian Retrospective Study. J Neurol Neurosurg Psychiatry. 2015;86(3):32430. doi:10.1136/jnnp-2014-307822</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Cilia R, Bonvegna S, Straccia G, Andreasi NG, Elia AE, Romito LM et al. Effects of COVID-19 on Parkinson’s Disease clinical features: a Community-Based Case-Control Study. Mov Disord. 2020. [Ahead of print, published online May 25, 2020]. doi:10.1002/mds.28170</mixed-citation><mixed-citation xml:lang="en">Cilia R, Bonvegna S, Straccia G, Andreasi NG, Elia AE, Romito LM et al. Effects of COVID-19 on Parkinson’s Disease clinical features: a Community-Based Case-Control Study. Mov Disord. 2020. [Ahead of print, published online May 25, 2020]. doi:10.1002/mds.28170</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Papa SM, Brundin P, Fung VSC, Kang UJ, Burn DJ, Colosimo C et al. MDS-Scientific Issues Committee. Impact of the COVID-19 Pandemic on Parkinson’s Disease and movement disorders. Mov Disord. 2020;35(5):711-715. doi:10.1002/mds.28067</mixed-citation><mixed-citation xml:lang="en">Papa SM, Brundin P, Fung VSC, Kang UJ, Burn DJ, Colosimo C et al. MDS-Scientific Issues Committee. Impact of the COVID-19 Pandemic on Parkinson’s Disease and movement disorders. Mov Disord. 2020;35(5):711-715. doi:10.1002/mds.28067</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Hribar CA, Cobbold PH, Church FC. Potential role of vitamin D in the elderly to resist COVID-19 and to slow progression of Parkinson’s Disease. 2020;10(5): E 284. doi:10.3390/brainsci10050284</mixed-citation><mixed-citation xml:lang="en">Hribar CA, Cobbold PH, Church FC. Potential role of vitamin D in the elderly to resist COVID-19 and to slow progression of Parkinson’s Disease. 2020;10(5): E 284. doi:10.3390/brainsci10050284</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Rejdak K, Grieb P. Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. Mult Scler Relat Disord. 2020;42:102163. doi:10.1016/j.msard.2020.102163</mixed-citation><mixed-citation xml:lang="en">Rejdak K, Grieb P. Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. Mult Scler Relat Disord. 2020;42:102163. doi:10.1016/j.msard.2020.102163</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
